3/3 In collaboration with Dr. Johan Bengzon, Dr. Anna Darabi, and Dr. Peter Siesjö (Lund University), as well as @AsgardThx, we seek to change the landscape of treatment for aggressive GBM tumors. For more details: https://t.co/wqhoBBs2IG #ABTA #Glioblastoma #Immunotherapy

2/3 Here, we will reprogram tumor cells into type 1 conventional dendritic cells (cDC1s) by intra-tumoral delivery of cDC1-inducing transcription factors in glioblastoma (GBM). Since GBM is highly immunosuppressive, cDC1 reprogramming offers a strategy to restore immunogenicity!

1/3 It’s an honor to share that our lab was awarded a Discovery grant from the American Brain Tumor Association (ABTA) for the project “In vivo Dendritic Cell Reprogramming as a New Immunotherapy for Glioblastoma”. @theABTA

4/4 Our project includes collaboration of Dr. Inge Marie Svane (Herlev Hospital), Dr. Axel Hyrenius-Wittsten (Lund University), and @AsgardThx . We greatly appreciate this donation from Mats Paulsson Foundation supporting the development of Lund University

3/4 This grant will explore the innovation path of applying dendritic cell reprogramming to selectively expand tumor-reactive tumor-infiltrating lymphocytes (TILs). The end goal is to advance TIL therapy pipelines with improved effectiveness.

2/4 Bringing a dynamic research-to-innovation environment within Medicon Village, this foundation fulfills its commitment to society by supporting academic research in medicine and life sciences in Skåne County.

1/4 Great to share that our lab was awarded a research grant from the Mats Paulsson Foundation for Research, Innovation and Societal Development for the project “Advancing Reactive Tumor-Infiltrating Lymphocyte Therapy with Cellular Reprogramming”.

2/2 Exploring the sea of immune cell diversity, our work successfully maps future lanes for dendritic cell reprogramming and cancer immunotherapy! Illustration by Avesta Rastan ( https://t.co/4w9ZRmTIhY) Read the full paper here:

1/2 Sharing exciting news! ✨ Our recently published paper “Anchored screening identifies transcription factor blueprints underlying dendritic cell diversity and subset-specific anti-tumor immunity” has been selected for the cover of the October issue of Immunity! @ImmunityCP

3/3 By collaborating with Karolinska Institutet, Peng will explore SM-assisted cDC1 reprogramming as a strategy to promote anti-tumor immunity. Way to go, Peng! For more info see:

2/3 cDC1 reprogramming offers great immunotherapeutic promise. Yet, viral-mediated transcription factor delivery presents challenges of safety, cost, and scalability. Replacing TFs with SMs can potentially surpass these roadblocks.

1/3 Congrats to our team member Peng Wei, who was awarded a SciLifeLab PULSE Postdoctoral Fellowship for his project SMARD, which will develop small molecule (SM)-assisted reprogramming to type 1 conventional dendritic cells (cDC1)!

2/2 Yet, dendritic cells had another go with @AbigailRAltman, who won Best Poster Award with "Transcription factor blueprints underlying dendritic cell diversity", now out in Immunity ( https://t.co/54htl0264Q). Congrats to both! It's great to have our contributions recognized!

1/2 Celebrating a double win!✨ Yesterday, at the Lund Stem Cell Center (LSCC) retreat, @ervin_ascic was awarded the Article of the Year Award with our Science paper "In vivo dendritic cell reprogramming for cancer immunotherapy" ( https://t.co/yPDqKmqecV)

3/3 If you feel you can contribute, reach out to mariana_faria.lopes@med.lu.se with a possible protocol title and small description. Let’s connect to push forward a guide for cell engineering and reprogramming strategies! @SpringerNature

2/3 The volume will cover: engineering immune cells with cellular reprogramming; viral and non-viral immune engineering; synthetic biology and genome editing to advance next-generation immune cells; clinical translation of cell engineering and reprogramming-based immunotherapies.

1/3 Call for Authors! We are currently editing a volume on Cellular Reprogramming for Immunotherapy for the Methods in Molecular Biology series (Springer Nature). This volume will steer the future of the field and is a great way to share your lab’s protocols!

Huge thanks to Prof. Allison, and congrats to Ervin, who masterfully defended the promise of cell reprogramming for cancer immunotherapy!

We are proud to announce that @ervin_ascic successfully defended his PhD yesterday with the special honor of Nobel Laureate James Allison as opponent! ✨ Ervin’s work makes a strong contribution showing that in vivo dendritic cell reprogramming is paving the way toward the clinic

@luisfholiveira @AbigailRAltman @ilya_ibc @ervin_ascic @halitzki @nmalavika05 @pedrocunha37 @lunduniversity @Lund_Stem @cnc_uc @AsgardThx @medeea_matei @FRosa93 @_CristianaPires @IsabelUlmert @katha_lahl @KharasLab @TheYuanLab 17/17 🙏🏻 A big thank you to all the funding agencies for making this possible: @ERC_Research, @HorizonEU, @Cancerfonden, @Vetenskapsradet, @novonordiskfond, @fct_pt, #NextgenerationEU, @CancerResearch.